



May 04, 2022

PROTAC diastereomer Design (negative control)

boc.protac¹¹BOC Sciences

1

dx.doi.org/10.17504/protocols.io.e6nvwk8o7vmk/v1

PROTAC

boc.protac

Diastereomers are stereoisomers in which molecules have two or more chiral centers and the relationship between molecules is not mirrored. In PROTAC drug development, in order to evaluate the pharmacokinetics of a single diastereomer or mixture of diastereomers, manufacturers should quantitatively analyze samples from the early stages of drug development for a single diastereomer in vivo. This will allow the assessment of the possibility of mutual transformation as well as the distribution of absorption, distribution, biotransformation and excretion (ADBE) of individual isomers. When the drug is a raceme and the pharmacokinetic characteristics of the isomers are different, the manufacturer should monitor the diastereomer separately to determine properties such as dose linearity and the effects of metabolic or excretory changes and drug-drug interactions.

As a leading service provider in drug discovery and development, BOC Sciences is fully qualified and committed to providing one-stop PROTAC[®] development services, which has become a promising strategy in the field of small molecular drug discovery. With a comprehensive and advanced platform, we design [PROTAC diastereomer](#) to customers around the world to meet new drug discovery goals.

DOI

dx.doi.org/10.17504/protocols.io.e6nvwk8o7vmk/v1<https://ptc.bocsci.com/services/protac-diastereomer-design-negative-control.html>

boc.protac 2022. PROTAC diastereomer Design (negative control) .
protocols.io
<https://dx.doi.org/10.17504/protocols.io.e6nvwk8o7vmk/v1>



protocol ,

May 04, 2022

May 04, 2022

61938